✦ LIBER ✦

How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting

✍ Scribed by Anna S. F. Lok

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 93 KB
Volume: 14
Category: Article
ISSN: 1527-6465
DOI: 10.1002/lt.21616

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Management of the hepatitis B virus in t

Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective

✍ Norah Terrault; Bruno Roche; Didier Samuel 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB

Outcomes in liver transplant recipients

Outcomes in liver transplant recipients with hepatitis B virus: Resistance and recurrence patterns from a large transplant center over the last decade

✍ Guy W. Neff; Christopher B. O'Brien; Jose Nery; Norah Shire; Marzia Montalbano; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB

Hepatitis B virus (HBV) recurrence following liver transplantation (LTx) has been controllable primarily with the use of hepatitis B immune globulin (HBIg) and lamivudine (LAM). However, HBV resistance to LAM and/or HBIg has become an increasing problem prompting the use of newer antiviral agents. T

Relationship between the interleukin-28b

Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus–induced graft inflammation and the response to antiviral therapy after liver transplantation

✍ Dennis Eurich; Sabine Boas-Knoop; Martin Ruehl; Maria Schulz; Esperanza D. Carri 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 293 KB

Up to 30% of liver transplants will develop graft cirrhosis within 5 years after liver transplantation (LT) due to recurrent HCV-infection forwarding accelerated graft damage. Genetic variants of cytokines involved in the immune response may contribute to the degree of graft inflammation, fibrosis p